RCS - ReNeuron Group plc - Investor Presentation

ReNeuronAnnouncement

28/01/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220128:nRSb9134Za&default-theme=true

RNS Number : 9134Z  ReNeuron Group plc  28 January 2022

ReNeuron Group plc

("ReNeuron" or the "Company")

 

Investor Presentation

 

ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell based Exosome
Technologies, announces that it will provide a live presentation and Q&A
for investors on Friday 4 February 2022 at 12.00pm (GMT).

 

CEO, Olav Hellebø and CFO, Catherine Isted will cover the recent strategic
update and there will be an opportunity to ask questions.

 

The presentation will be hosted through the digital platform Investor Meet
Company. Investors can sign up to Investor Meet Company for free and request
to meet ReNeuron Group plc via the following link:
https://www.investormeetcompany.com/reneuron-group-plc/register-investor
(https://www.investormeetcompany.com/reneuron-group-plc/register-investor)

 

Questions can be submitted pre-event via your IMC dashboard or in real time
during the presentation, via the "Ask a Question" function.  Whilst the
Company may not be in a position to answer every question it receives, it will
address the most prominent within the confines of regulations and information
already disclosed to the market through regulatory notifications. A recording
of the presentation, a PDF of the slides used, and responses to the Q&A
session will be available on the Investor Meet Company platform
afterwards. No new price sensitive information will be disclosed, and a PDF
of the presentation will be uploaded to the Company's website.

 

Contacts:

 

 ReNeuron                                                 www.reneuron.com/investors (http://www.reneuron.com/investors)
 Olav Hellebø, Chief Executive Officer                    Via Walbrook PR
 Catherine Isted, Chief Financial Officer

 Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)  +44 (0)20 7710 7600

 Ben Maddison, Stewart Wallace

 Allenby Capital Limited (Joint Broker)                   +44 (0)20 3328 5656
 James Reeve/George Payne (Corporate Finance)
 Stefano Aquilino (Sales & Corporate Broking)

 Walbrook PR (Media & Investor Relations)                 +44 (0)20 7933 8780 or reneuron@walbrookpr.com
 Paul McManus/Alice Woodings                              +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

About ReNeuron

 

ReNeuron is a UK based Proprietary Stem Cell based Exosome Technologies
company, harnessing its unique stem cell technologies to develop 'off the
shelf' treatments for disease with significant unmet needs.

 

ReNeuron's stem cell derived proprietary Exosome Technology platform offers a
delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins,
small molecules and genes. The Company has a growing number of partner
collaborations with Global Pharma, Biotech and academic partners in this
fast-expanding area of scientific and commercial interest. ReNeuron also has
the ability through its conditionally immortalised induced pluripotent stem
cell (iPSC) platform to make allogeneic tissue cells of choice and has the
potential to produce exosomes with tissue specific targeting ability.

 

The Company also has a Phase 2 cell therapy candidate in retinitis pigmentosa
which it plans to out-license and also has out-licensed its CTX programme in
stroke disability to Fosun in China.

 

ReNeuron's shares are traded on the London AIM market under the symbol
RENE.L.  For further information visit www.reneuron.com
(http://www.reneuron.com)

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABRMMTMTITTBT